ClinicalTrials.gov
public full text
Public Domain
DPP-4 Inhibition and TZD for DM Prevention
To determine whether treatment with the diabetes medication, Januvia (sitagliptin), with or without another diabetes medicine, Actos (pioglitazone), will improve insulin secretion and insulin response individuals with Impaired Glucose Tolerance (IGT), a form of prediabetes.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Proponer mejoras a los procesos de adquisición y distribución de nph e insulinas regulares por parte de sistema único de salud (sus)#931426
- To Evaluate the Hormonal Response to Low Blood Sugar After a Single Oral Dose of AZD1656 Suspension#834832
- Metformin Exposure and Pediatric Asthma-Related Outcomes in the Context of Obesity, Diabetes, and Metabolic Syndrome: A Scoping Review Protocol#1175000
- Therapeutic Efficacy and Safety Evaluation of AI in the Management of Diabetes: A RCT Trial#141168
- Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease#481700
Record · ID 867847
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive